Klaus Michael Debatin

Title: Klaus Michael Debatin: Innovator in Neuroectodermal Tumor Treatment

Introduction

Klaus Michael Debatin is a notable inventor based in Ulm, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of neuroectodermal tumors. His innovative work has led to the development of a patent that showcases the potential of betulinic acid and its derivatives.

Latest Patents

Debatin holds a patent for "Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor." This invention is directed towards utilizing betulinic acid and its derivatives as potent anti-neuroectodermal agents. The discovery highlights the effectiveness of these compounds in treating neuroectodermal tumors, especially those resistant to conventional chemotherapy. The patent also includes novel compounds and pharmaceutical compositions aimed at improving treatment outcomes for patients.

Career Highlights

Throughout his career, Klaus Michael Debatin has been associated with the Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. His work has been instrumental in advancing research in cancer treatment, particularly focusing on neuroectodermal tumors. His dedication to innovation in this field has garnered attention and respect from his peers.

Collaborations

Debatin has collaborated with esteemed colleagues such as Simone Fulda and Manfred Wiessler. These partnerships have contributed to the advancement of research and development in cancer therapies, enhancing the impact of their collective work.

Conclusion

Klaus Michael Debatin's contributions to the treatment of neuroectodermal tumors through his innovative patent demonstrate his commitment to improving patient care. His work continues to inspire advancements in medical research and treatment methodologies.